Leerink analyst Joseph Schwartz raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $50.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel MomentumJune 16, 2026 10:19 AM Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX)June 16, 2026 9:00 AM Leerink: 'CIRRUS Part D data continue to look supportive of EDG-7500’s potential'June 16, 2026 8:55 AM SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fallJune 16, 2026 8:18 AM EDGEWISE reports Phase 2 HCM trial results for EDG-7500June 16, 2026 7:00 AM Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)June 16, 2026 7:00 AM